Repositioning Candidate Details
| Candidate ID: | R0411 |
| Source ID: | DB02709 |
| Source Type: | approved; experimental; investigational |
| Compound Type: | small molecule |
| Compound Name: | Resveratrol |
| Synonyms: | |
| Molecular Formula: | C14H12O3 |
| SMILES: | OC1=CC=C(\C=C\C2=CC(O)=CC(O)=C2)C=C1 |
| Structure: |
|
| DrugBank Description: | Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenolic phytoalexin. It is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as cis-(Z) and trans-(E) isomers. The trans- form can undergo isomerisation to the cis- form when heated or exposed to ultraviolet irradiation. In a 2004 issue of Science, Dr. Sinclair of Harvard University said resveratrol is not an easy molecule to protect from oxidation. It has been claimed that it is readily degraded by exposure to light, heat, and oxygen. However, studies find that Trans-resveratrol undergoes negligible oxidation in normal atmosphere at room temperature. |
| CAS Number: | 501-36-0 |
| Molecular Weight: | 228.2433 |
| DrugBank Indication: | Being investigated for the treatment of Herpes labialis infections (cold sores). |
| DrugBank Pharmacology: | Resveratrol, a phytoalexin, has been found to inhibit herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) replication in a dose-dependent, reversible manner, although this is only one of its many pharmaceutical properties. In some countries where there is higher consumption of red wine, there appears to be a lower incidence of heart disease. Other benefits of resveratrol include its anti-inflammatory and antioxidant effects. In preclinical studies, Resveratrol has been found to have potential anticancer properties. |
| DrugBank MoA: | Resveratrol suppresses NF-kappaB (NF-kappaB) activation in HSV infected cells. Reports have indicated that HSV activates NF-kappaB during productive infection and this may be an essential aspect of its replication scheme [PMID: 9705914]. |
| Targets: | Ribosyldihydronicotinamide dehydrogenase [quinone]; Casein kinase II subunit alpha; Prostaglandin G/H synthase 1; Prostaglandin G/H synthase 2; Arachidonate 15-lipoxygenase; Arachidonate 5-lipoxygenase; Aryl hydrocarbon receptor; Phosphatidylinositol 4-kinase type 2-beta; Integrin alpha-5; Integrin beta-3; Amyloid beta A4 protein; Alpha-synuclein; NAD-dependent protein deacetylase sirtuin-1; Estrogen receptor alpha; Melatonin receptor type 1A; Melatonin receptor type 1B; C-type lectin domain family 14 member A; Nuclear receptor subfamily 1 group I member 2; Nuclear receptor subfamily 1 group I member 3; Solute carrier family 2, facilitated glucose transporter member 1; Carbonyl reductase [NADPH] 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; RAC-alpha serine/threonine-protein kinase; Far upstream element-binding protein 2; Tyrosine--tRNA ligase, cytoplasmic |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|